| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PSTV Stock Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases.
Plus Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$0.41 |
| Beta | 0.42 |
| 1 Month Change | -12.72% |
| 3 Month Change | -50.28% |
| 1 Year Change | -82.06% |
| 3 Year Change | -95.86% |
| 5 Year Change | -99.91% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| PSTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.3% | 10.3% | 6.6% |
| 1Y | -82.1% | -24.3% | -18.4% |
Return vs Industry: PSTV underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: PSTV underperformed the US Market which returned -18.4% over the past year.
Price Volatility
| PSTV volatility | |
|---|---|
| PSTV Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 13.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PSTV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PSTV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 14 | Marc Hedrick | https://www.plustherapeutics.com |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment.
Plus Therapeutics Fundamentals Summary
| PSTV fundamental statistics | |
|---|---|
| Market Cap | US$11.15m |
| Earnings (TTM) | -US$14.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs PSTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSTV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.98m |
| Gross Profit | -US$5.98m |
| Other Expenses | US$8.81m |
| Earnings | -US$14.79m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 43.2% |
How did PSTV perform over the long term?
See historical performance and comparisonValuation
Is PSTV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PSTV?
Other financial metrics that can be useful for relative valuation.
| What is PSTV's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$11.15m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does PSTV's PB Ratio compare to its peers?
| PSTV PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
ONVO Organovo Holdings | 0.5x | n/a | US$15.4m |
ALLR Allarity Therapeutics | 1.1x | 14.6% | US$16.6m |
BBI Brickell Biotech | 0.9x | 16.5% | US$14.8m |
IPIX Innovation Pharmaceuticals | 3.3x | n/a | US$19.0m |
PSTV Plus Therapeutics | 0.8x | -19.7% | US$11.1m |
Price-To-Book vs Peers: PSTV is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does PSTV's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: PSTV is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is PSTV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate PSTV's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PSTV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PSTV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PSTV's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PSTV's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Plus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-19.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSTV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PSTV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PSTV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PSTV is forecast to have no revenue next year.
High Growth Revenue: PSTV is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PSTV's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Plus Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
24.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PSTV is currently unprofitable.
Growing Profit Margin: PSTV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PSTV is unprofitable, but has reduced losses over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare PSTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: PSTV has a negative Return on Equity (-101.04%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Plus Therapeutics's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PSTV's short term assets ($22.1M) exceed its short term liabilities ($4.9M).
Long Term Liabilities: PSTV's short term assets ($22.1M) exceed its long term liabilities ($5.0M).
Debt to Equity History and Analysis
Debt Level: PSTV has more cash than its total debt.
Reducing Debt: PSTV's debt to equity ratio has reduced from 217% to 43.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PSTV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PSTV has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 18.7% each year.
Discover healthy companies
Dividend
What is Plus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PSTV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PSTV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PSTV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PSTV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTV has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Marc Hedrick (58 yo)
18.08yrs
Tenure
US$1,667,279
Compensation
Dr. Marc H. Hedrick, M.D. has been the President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr. Hedric...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD749.40K).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: PSTV's management team is considered experienced (2.6 years average tenure).
Board Members
Experienced Board: PSTV's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PSTV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118%.
Top Shareholders
Company Information
Plus Therapeutics, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Plus Therapeutics, Inc.
- Ticker: PSTV
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$11.148m
- Shares outstanding: 22.20m
- Website: https://www.plustherapeutics.com
Number of Employees
Location
- Plus Therapeutics, Inc.
- 4200 Marathon Boulevard
- Suite 200
- Austin
- Texas
- 78756
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/26 00:00 |
| End of Day Share Price | 2022/06/24 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.